

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Expert Committee on Biological Standardization

Thirty-fourth Report

World Health Organization
Technical Report Series
700



World Health Organization, Geneva 1984

ISBN 92 4 120700 0

© World Health Organization 1984

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

83/5944 – Schüler S.A. – 6000

CONTENTS

	Page
General	7
International standards and international reference preparations.....	7
Paper discs.....	8
Rabies vaccine.....	9
Tuberculin.....	9
The potency of diphtheria and tetanus toxoids, adsorbed.....	11
Calibration and expression of results of assays of human gonadotrophins	11

SUBSTANCES

Antibiotics

1. Amikacin.....	12
2. Erythromycin.....	12
3. Netilmicin.....	13
4. Sisomicin.....	13
5. Tobramycin.....	13

Antibodies

6. <i>Clostridium botulinum</i> type B antitoxin, equine.....	14
7. Monoclonal antibodies.....	14

Antigens

8. Lecithin (bovine heart).....	14
9. Rabies vaccine.....	15
10. Tetanus toxoid, adsorbed.....	15
11. Purified protein derivative of mammalian tuberculin.....	16
12. Short ragweed pollen extract.....	16
13. Timothy grass pollen extract.....	17

Blood products and related substances

14. Anti-C complete and anti-E complete blood typing sera.....	17
15. Anti-varicella zoster immunoglobulin.....	18
16. Heparin.....	18
17. Thromboplastin, bovine, combined.....	18
18. Thromboplastin, human, plain.....	19

Endocrinological and related substances

19. Insulins.....	19
20. Parathyroid hormone 1-34 peptides, bovine and human.....	20
21. Proinsulins and human insulin C-peptide.....	20
22. Prolactin, human, for immunoassay.....	20
23. Thyroid stimulating hormone, human, for immunoassay.....	21

Miscellaneous substances

24. Endotoxin.....	21
25. Human autoantibody sera for pattern recognition in immunofluorescence.....	22
26. Rubella virus (strain M-33) and rubella antiserum, rabbit.....	22
27. Snake venoms and antivenoms.....	23

REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

28. Requirements for diphtheria toxoid, pertussis vaccine, tetanus toxoid, and combined vaccines.....	23
29. Requirements for Rift Valley fever vaccine (live, attenuated) for veterinary use.....	23
30. Requirements for typhoid vaccine (live attenuated, Ty 21a, oral).....	24
31. Biological products made by recombinant DNA technology.....	25
32. Intravenous immunoglobulins.....	25

Acknowledgements	25
-------------------------------	----

ANNEXES

Annex 1. Requirements for diphtheria toxoid, pertussis vaccine, tetanus toxoid, and combined vaccines (Addendum 1983).....	26
Annex 2. Requirements for Rift Valley fever vaccine (live, attenuated) for veterinary use.....	28
Annex 3. Requirements for typhoid vaccine (live attenuated, Ty 21a, oral).....	48
Annex 4. Biological substances: international standards, reference preparations, and reference reagents.....	69
Annex 5. Requirements for biological substances and other sets of recommendations.....	72

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 27 September–3 October 1983

Members

- Mr V.F. Davey, Director, Science, Commonwealth Serum Laboratories, Parkville, Australia
Professor S.G. Dzagurov, Director, Tarasevič State Research Institute for the Standardization and Control of Medical Biological Preparations, Ministry of Health, Moscow, USSR
Dr H.W. Krijnen, Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands
Dr J.W. Lightbown, Head, Division of Antibiotics, National Institute for Biological Standards and Control, London, England
Mr J. Lyng, Head, Laboratory for Biological Standardization, State Serum Institute, Copenhagen, Denmark
Dr H. Mirchamsy, Associate Director, Razi State Institute of Serum and Vaccine Production, Teheran, Islamic Republic of Iran
Professor G. Swaniker, Head, Department of Chemical Pathology, University of Ghana Medical School, Accra, Ghana (*Vice-Chairman*)
Dr D.P. Thomas, Head, Division of Blood Products, National Institute for Biological Standards and Control, London, England (*Rapporteur*)
Dr Tsou Pang-chu, Division of Bacterial Vaccines, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China
Dr W.W. Wright, Senior Scientist, Drug Standards Division, The United States Pharmacopeia, The National Formulary, Rockville, MD, USA (*Chairman*)

Secretariat

- Dr J.N. Ashworth, Vice-President, Scientific Affairs, Cutter International, Division of Miles Laboratories, Inc., Emeryville, CA, USA (*Temporary Adviser*)
Dr D.R. Bangham, Head, Division of Hormones, National Institute for Biological Standards and Control, London, England (*Temporary Adviser*)
Dr W.J. Duimel, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)
Professor W. Hennessen, Berne, Switzerland (*Temporary Adviser*)
Dr E. Loeliger, Interne Geneeskunde, Academisch Ziekenhuis, Leiden, Netherlands (*Temporary Adviser*)
Dr F.T. Perkins, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)
Dr J. Petriccioni, Director, Office of Biologics, National Center for Drugs and Biologics, Food and Drug Administration, Bethesda, MD, USA (*Temporary Adviser*)

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Thirty-fourth Report

GENERAL

The WHO Expert Committee on Biological Standardization met in Geneva from 27 September to 3 October 1983. The meeting was opened on behalf of the Director-General by Dr B. Sankaran, Director, Division of Diagnostic, Therapeutic, and Rehabilitative Technology.

International standards and international reference preparations

In the past, two categories of standard preparations with defined international units of activity have been established, namely, international biological standards and international biological reference preparations. The need for two categories, both serving the same function, had been questioned and was examined by the Committee.

The category of international biological reference preparations was first introduced during a period of rapid development in the antibiotic field. Because the establishment of an international standard, with its defined unit of activity, was a lengthy procedure, it was considered necessary to make internationally accepted reference preparations available as quickly as possible, to avoid the confusion arising from a multiplicity of national units. The stated intention was "to temporarily satisfy a need which, at a later date, could be met by replacement of such international reference preparations by international standards" (WHO Technical Report Series, No. 172, 1959, p. 6). At that period an international reference preparation did not define an international unit of activity. Later, however, the Committee decided that an international unit could be assigned not only to an international standard, but also to an international reference preparation (WHO Technical Report Series, No. 259, 1963, p. 6). This procedure was followed, for example, for the International Reference Preparation of Amphotericin B and the International Reference Preparation of Vancomycin (WHO Technical Report

Series, No. 274, 1964, p. 8). Subsequently, many international reference preparations defining international units of activity were established on the basis of collaborative assays. They have served their intended function satisfactorily but have not been reclassified as international standards.

The Committee, at its present meeting, agreed that it was no longer necessary for international reference preparations with defined units of activity to constitute a separate category, and that all such materials could be considered functionally to be international standards. The question of whether it would be desirable to rename the international biological reference preparations already established as international biological standards was discussed, and it was agreed that to do so would probably cause confusion because of the extensive scientific literature in which their existing names had been used.

The Committee decided that, in the future, a single category of standard preparations would be established for the purpose of defining international units of activity, namely, international biological standards. It would, nevertheless, remain necessary to designate certain materials as international biological reference preparations, but that designation would be restricted to preparations that did not define international units of activity.

The Committee agreed that all international standards and international reference preparations with defined units of activity on which the World Health Assembly had not yet made a recommendation should be presented to the Health Assembly as soon as possible. This procedure was necessary to ensure the continued international acceptance of the various international units of biological activity.

Paper discs

In Part A, section 5.2.1 of the *Requirements for antimicrobial susceptibility tests. I. Agar diffusion tests using antimicrobial susceptibility discs* (WHO Technical Report Series, No. 673, 1982, pp. 156–159) it is stated that for *assays of content* of blank discs suitable paper should be used to prepare standard discs; that is, discs impregnated with standard antimicrobial agents. Whether the blank discs to be used routinely by a control laboratory are suitable may be determined by comparing how they perform in the assay system with the performance of blank discs of known suitability.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30797

